Point72 (DIFC)’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 (DIFC)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,800	Closed	-$4.09M	–	1755
2025 Q2	$4.09M	Buy	7,800 +6,000	+333%	+$3.35M	0.16%	172
2025 Q1	$1.14M	Buy	1,800 +800	+80%	+$550K	0.05%	441
2024 Q4	$712K	Buy	+1,000	New	+$839K	0.03%	551
2024 Q3	–	Sell	-500	Closed	-$526K	–	1755
2024 Q2	$526K	Sell	500 -1,300	-72%	-$1.26M	0.02%	663
2024 Q1	$1.73M	Buy	+1,800	New	+$1.71M	0.05%	429

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 (DIFC)'s REGN Position: Q3 2025 in Review

Point72 (DIFC) reduced its Regeneron Pharmaceuticals (REGN) stake by 30% in Q3 2025, selling an estimated $1.45M and leaving 5,840 shares worth $3.28M. The position accounts for 0.22% of the portfolio, ranked #96.

Point72 (DIFC) first reported a position in REGN in Q4 2024 and has held it in 3 quarters since. The position peaked at $4.41M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Point72 (DIFC) held 5,840 shares of Regeneron Pharmaceuticals worth $3.28M as of Q3 2025.
Point72 (DIFC) sold 2,558 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.45M.
Regeneron Pharmaceuticals made up 0.22% of Point72 (DIFC)'s portfolio in Q3 2025, its #96 holding.
Point72 (DIFC) first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
Point72 (DIFC)'s Regeneron Pharmaceuticals position peaked at $4.41M in Q2 2025.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.